Skip to content


  • Poster Presentation
  • Open Access

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2

  • 1, 2,
  • 1,
  • 3,
  • 1,
  • 4,
  • 5,
  • 5,
  • 1,
  • 6,
  • 2,
  • 7 and
  • 1, 7
Breast Cancer Research20057 (Suppl 2) :P1.11

  • Published:


  • Breast Cancer
  • Breast Cancer Susceptibility
  • Male Breast Cancer
  • Female Breast Cancer
  • Breast Cancer Family


A conventional model of inherited breast cancer susceptibility is that disease risks are affected by mutations in a small number of genes causing a high risk of the disease and by a larger number of lower risk gene variants probably interacting together [1]. Model-based linkage analysis in multiple-case families, followed by positional cloning, led to the identification of BRCA1 and BRCA2. The cancer risks conferred by mutations in these genes are now well established, but together they explain only approximately 25% of the overall excess familial risk. Families with at least four cases of breast cancer and at least one case of ovarian cancer can be attributed largely to BRCA1. Multiple-case families with at least one case of male breast cancer are mainly due to BRCA2. But the majority of families with four or five cases of female breast cancer diagnosed before the age of 60 are not due to BRCA1 or BRCA2. This has been taken as evidence that one or more moderate-risk to high-risk breast cancer susceptibility genes still remain to be identified [2].


There have been several linkage claims since BRCA1 and BRCA2 were identified, but none of these have been replicated in other, often larger, studies. Most studies, however, are heavily underpowered to detect a new breast cancer locus by linkage in the presence of substantial genetic heterogeneity. The Breast Cancer Linkage Consortium is currently compiling genome-wide linkage data on approximately 200 families in which the role of BRCA1 or BRCA2 has been excluded with >90% certainty. This comprises the largest post-BRCA1/2 linkage search effort in breast cancer families in the world to date. These families are characterised by the presence of at least three cases of breast cancer diagnosed before the age of 60, and no cases of ovarian or male breast cancer.


Here we present the Dutch contribution to this effort, including GENEHUNTER analysis of 56 families in which 208 patients were genotyped at 410 microsatellite markers. Allowing for heterogeneity, there were two regions, on 1q and 15q, that gave lod scores of 1.40 (α = 0.12) and 1.19 (α = 0.29), respectively. Lod scores for all other markers were <1.0. In non-parametric analysis, lod scores >1.0 were found for one or more markers at 4p, 6q, 7q, 9p, 15q, and 21q. All of these regions are currently being followed up by additional flanking marker typings.

Authors’ Affiliations

Department of Human & Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
Department of Clinical Genetics, Erasmus University, Rotterdam, The Netherlands
Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands
Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Department of Human Genetics, University of Nijmegen, The Netherlands
Foundation for the Detection of Hereditary Tumors, Leiden, The Netherlands
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands


  1. Antoniou AC, Pharoah PDP, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002, 86: 76-83. 10.1038/sj.bjc.6600008.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Breast Cancer Linkage Consortium, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.View ArticlePubMedPubMed CentralGoogle Scholar


© BioMed Central 2005